ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Devil's claw (Harpagophytum procumbens): is the buzz in Google justified?
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Harpagophytum procumbens in musculoskeletal disorders: current evidence and comparison with NSAIDs.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic muscle and joint pain affect many people. However, current treatment options harbor a considerable risk of adverse drug reactions, which is why the search for other treatment alternatives is constantly expanding. As a result, research is also focusing on plant-based products. These include devil's claw, a medicinal plant from the sesame family, which is native to the African continent and is used there as a traditional remedy. In this study, 16 different criteria were selected for a critical analysis of devil's claw products, which included aspects such as drug-drug interactions, adverse drug reactions, and recommended daily dose, and 88 products were analyzed with the help of these criteria. Furthermore, products classified as food supplements, dietary supplements, and herbal medicinal products were compared with each other. Our goal was to analyze how consumers are informed, with a focus on consumer safety. The primary objective was not to analyze the actual ingredients of the products or to compare them based on their composition. The results almost invariably show the pharmaceutical reliability of herbal medicinal products. In contrast, products marketed as food supplements and dietary supplements have questionable reliability, as most products in these categories allow manufacturers more freedom and impose fewer controls and requirements. Devil's claw products labeled as food or dietary supplement show significant gaps in consumer information compared to herbal medicinal products. Product naming and packaging are often suggestive, potentially misleading consumers. Our study shows that food supplements and dietary supplements are clearly pursuing financial interests, and that consumer protection is often neglected in the process. The study analysis also revealed a limited number of clinical studies, no long-term studies, and poor methodological quality, undermining their reliability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.